AusCann : Releases Cannabinoid Medical Education Resources

ASX RELEASE

AusCann Releases Cannabinoid Medical

Education Resources

Highlights

• • AusCann releases online education courses as part of its Medical Outreach Program to support Australian health professionals make informed decisions regarding cannabinoid therapeutics.

Tuesday, 2 October 2018 - Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or 'the Company') is pleased to advise it has today released a series of online courses for Australian health professionals, as a part of its Medical Outreach Program.

AusCann committed early to an outreach program to support Australian medical practitioners and health professionals with the necessary information to confidently make decisions regarding use of cannabinoid medicines.

Dr Danial Schecter, a Canadian clinician with expertise gained from working in the Canadian medical cannabis market and managing his own cannabinoid medical clinics, was appointed AusCann's Chief Medical Advisor in June 2017. The Company subsequently appointed three medical liaison managers (MLMs) to build the outreach team to provide guidance and information to the medical community. Combined, the MLM team has nearly 50 years of experience in the health sector and its managers have worked in senior roles with some of the world's leading pharmaceutical companies.

The online courses represent the latest component of AusCann's outreach program, developed with the assistance of Dr Schecter and experts in online pedagogical resources, as well as input from AusCann's Chairman, Dr Mal Washer.

"It is essential that Australian doctors are informed about the endocannabinoid system and cannabinoid therapeutics so that they can make informed decisions regarding treatment possibilities. Until it becomes part of the medical syllabus, there is a need to provide accessible, referenced, objective information about cannabinoid medicines that doctors and other health professionals can draw upon to inform their thinking," Dr Washer said.

The online courses were launched today under the Medical Portal on AusCann's website.

Link to access the portal:https://www.auscann.com.au/medical-portal.html

ENDS

For more information, please contact:

AusCann	For Investment Enquires	For Media Enquiries
Elaine Darby	Stewart Washer	Elodie Castagna
Managing Director	[e-mail]	FTI Consulting
[e-mail]	[phone]	[e-mail]
[phone]	[phone]

AusCann Group Holdings Ltd ACN 008 095 207www.auscann.com.au

Email:[e-mail]

Phone: [phone]

Suite 8, Level 2, Shenton House, 57 Shenton Avenue, Joondalup, WA 6027 AUSTRALIA

ASX RELEASE

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based pharmaceutical company that aims to produce high quality, economical, and clinically validated cannabinoid medicines. AusCann is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products. Through partnerships with industry experts, existing leading market participants and doctors, AusCann is building operations and educating the medical community about the benefits of cannabinoid medicines. Incorporated in 2014, AusCann holds the full set of necessary licences to grow and manufacture cannabinoid medicines in Australia. The company is initially targeting medications for neuropathic and chronic pain in Australia and Chile, whilst exploring global export opportunities.

AusCann Group Holdings Ltd ACN 008 095 207www.auscann.com.au

Email:[e-mail]

Phone: [phone]

Suite 8, Level 2, Shenton House, 57 Shenton Avenue, Joondalup, WA 6027 AUSTRALIA